{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:13:42Z","timestamp":1790626422223,"version":"4.1.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"am","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.metabol.2019.03.009","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T18:33:33Z","timestamp":1553711613000},"page":"153892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"S","title":["Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH)"],"prefix":"10.1016","volume":"103","author":[{"given":"Anya","family":"Rothenbuhler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"H\u00f6gler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0005","first-page":"333","article-title":"X-linked hypophosphataemia: a homologous disorder in humans and mice","volume":"14","author":"Tenenhouse","year":"1999","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ng1095-130","volume":"11","year":"1995","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.metabol.2019.03.009_bb0015","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.2005111185","article-title":"Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D","volume":"17","author":"Liu","year":"2006","journal-title":"J Am Soc Nephrol JASN"},{"issue":"11","key":"10.1016\/j.metabol.2019.03.009_bb0020","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms","volume":"174","author":"Che","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0030","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00223-010-9373-0","article-title":"Phenotype presentation of hypophosphatemic rickets in adults","volume":"87","author":"Beck-Nielsen","year":"2010","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0035","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/0022034516677528","article-title":"Phosphate and vitamin D prevent periodontitis in X-linked hypophosphatemia","volume":"96","author":"Biosse Duplan","year":"2017","journal-title":"J Dent Res"},{"issue":"1","key":"10.1016\/j.metabol.2019.03.009_bb0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3476(81)80951-1","article-title":"Long-term treatment of familial hypophosphatemic rickets with oral phosphate and 1 alpha-hydroxyvitamin D3","volume":"99","author":"Rasmussen","year":"1981","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0045","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1067\/mpd.2003.119","article-title":"Dental abnormalities in patients with familial hypophosphatemic vitamin D-resistant rickets: prevention by early treatment with 1-hydroxyvitamin D","volume":"142","author":"Chaussain-Miller","year":"2003","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0050","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00467-011-2046-z","article-title":"Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment","volume":"27","author":"Quinlan","year":"2012","journal-title":"Pediatr Nephrol Berl Ger."},{"issue":"8","key":"10.1016\/j.metabol.2019.03.009_bb0055","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1210\/jc.2003-030036","article-title":"Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets","volume":"88","author":"M\u00e4kitie","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0060","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00439-009-0631-z","article-title":"PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets","volume":"125","author":"Gaucher","year":"2009","journal-title":"Hum Genet"},{"issue":"8","key":"10.1016\/j.metabol.2019.03.009_bb0065","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1210\/jcem.86.8.7761","article-title":"Mutational analysis and genotype-phenotype correlation of the PHEX gene in X-linked hypophosphatemic rickets","volume":"86","author":"Holm","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2019.03.009_bb0070","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3892\/ijmm.2016.2796","article-title":"Seven novel and six de novo PHEX gene mutations in patients with hypophosphatemic rickets","volume":"38","author":"Li","year":"2016","journal-title":"Int J Mol Med"},{"issue":"1","key":"10.1016\/j.metabol.2019.03.009_bb0075","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2350-12-116","article-title":"Genetic diagnosis of X-linked dominant hypophosphatemic rickets in a cohort study: tubular reabsorption of phosphate and 1,25(OH) 2 D serum levels are associated with PHEX mutation type","volume":"12","author":"Morey","year":"2011","journal-title":"BMC Med Genet"},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0080","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2265.2010.03919.x","article-title":"Mutational analysis of PHEX, FGF23 and DMP1 in a cohort of patients with hypophosphatemic rickets","volume":"74","author":"Ruppe","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"10.1016\/j.metabol.2019.03.009_bb0085","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/jhg.2012.56","article-title":"Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets","volume":"57","author":"Beck-Nielsen","year":"2012","journal-title":"J Hum Genet"},{"issue":"6","key":"10.1016\/j.metabol.2019.03.009_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130729","article-title":"Whole exome sequencing reveals novel PHEX splice site mutations in patients with hypophosphatemic rickets","volume":"10","author":"Ma","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0095","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.bone.2008.06.002","article-title":"Mutational survey of the PHEX gene in patients with X-linked hypophosphatemic rickets","volume":"43","author":"Ichikawa","year":"2008","journal-title":"Bone."},{"issue":"1","key":"10.1016\/j.metabol.2019.03.009_bb0100","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect"},{"issue":"5","key":"10.1016\/j.metabol.2019.03.009_bb0105","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/BF00858154","article-title":"Assessment and interpretation of the tubular threshold for phosphate in infants and children","volume":"8","author":"Brodehl","year":"1994","journal-title":"Pediatr Nephrol Berl Ger"},{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00862587","article-title":"Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet","volume":"2","author":"Brodehl","year":"1988","journal-title":"Pediatr Nephrol Berl Ger"},{"issue":"6","key":"10.1016\/j.metabol.2019.03.009_bb0115","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1053\/j.ackd.2017.09.011","article-title":"Measurement and estimation of glomerular filtration rate in children","volume":"24","author":"Mian","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0120","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00467-012-2364-9","article-title":"Hypophosphatemia and growth","volume":"28","author":"Santos","year":"2013","journal-title":"Pediatr Nephrol Berl Ger."},{"issue":"1","key":"10.1016\/j.metabol.2019.03.009_bb0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4274\/jcrpe.v3i1.02","article-title":"Serum alkaline phosphatase levels in healthy children and evaluation of alkaline phosphatase z-scores in different types of rickets","volume":"3","author":"Turan","year":"2011","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"1","key":"10.1016\/j.metabol.2019.03.009_bb0130","first-page":"22","article-title":"Genu varum and genu valgum in children: differential diagnosis and guidelines for evaluation","volume":"22","author":"Greene","year":"1996","journal-title":"Compr Ther"},{"issue":"5","key":"10.1016\/j.metabol.2019.03.009_bb0135","doi-asserted-by":"crossref","first-page":"E954","DOI":"10.1210\/jc.2012-4133","article-title":"Cortical and trabecular bone density in X-linked hypophosphatemic rickets","volume":"98","author":"Cheung","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2019.03.009_bb0140","series-title":"Paediatric chemical pathology","article-title":"Clinical tests and refernce ranges","author":"Clayton","year":"1960"},{"key":"10.1016\/j.metabol.2019.03.009_bb0145","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jcem-20-3-364","article-title":"The normal range of serum inorganic phosphorus and its utility as a discriminant in the diagnosis of congenital hypophosphatemia","volume":"20","author":"Greenberg","year":"1960","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.metabol.2019.03.009_bb0150","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"Insogna KL. A clinician's guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter TO","year":"2011","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"17","key":"10.1016\/j.metabol.2019.03.009_bb0155","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0160","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12020-011-9512-z","article-title":"Evaluation of bone markers in hypophosphatemic rickets\/osteomalacia","volume":"40","author":"Nagata","year":"2011","journal-title":"Endocrine."},{"issue":"6","key":"10.1016\/j.metabol.2019.03.009_bb0165","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.bone.2008.02.014","article-title":"Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement","volume":"42","author":"Endo","year":"2008","journal-title":"Bone."},{"issue":"5","key":"10.1016\/j.metabol.2019.03.009_bb0170","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00223-017-0307-y","article-title":"Evaluation of a new fully automated assay for plasma intact FGF23","volume":"101","author":"Souberbielle","year":"2017","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"10.1016\/j.metabol.2019.03.009_bb0175","first-page":"3615","article-title":"Mutational analysis of PHEX gene in X-linked hypophosphatemia","volume":"83","author":"Dixon","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0180","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/(SICI)1098-1004(200004)15:4<383::AID-HUMU18>3.0.CO;2-#","article-title":"Identification of fifteen novel PHEX gene mutations in Finnish patients with hypophosphatemic rickets","volume":"15","author":"Tyynismaa","year":"2000","journal-title":"Hum Mutat"},{"issue":"1","key":"10.1016\/j.metabol.2019.03.009_bb0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/cen.13347","article-title":"Mutational analysis of PHEX, FGF23 and CLCN5 in patients with hypophosphataemic rickets","volume":"87","author":"Guven","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1016\/j.metabol.2019.03.009_bb0190","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3346\/jkms.2007.22.6.981","article-title":"PHEX gene mutations and genotype-phenotype analysis of Korean patients with hypophosphatemic rickets","volume":"22","author":"Song","year":"2007","journal-title":"J Korean Med Sci"},{"issue":"1","key":"10.1016\/j.metabol.2019.03.009_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1098-1004(200007)16:1<1::AID-HUMU1>3.0.CO;2-J","article-title":"PHEXdb, a locus-specific database for mutations causing X-linked hypophosphatemia","volume":"16","author":"Sabbagh","year":"2000","journal-title":"Hum Mutat"},{"issue":"9\u201310","key":"10.1016\/j.metabol.2019.03.009_bb0200","first-page":"1009","article-title":"Phosphate homeostasis and genetic mutations of familial hypophosphatemic rickets","volume":"28","author":"Razali","year":"2015","journal-title":"J Pediatr Endocrinol Metab JPEM."},{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2019.03.009_bb0210","article-title":"X-linked hypophosphatemia in Polish patients. 1. Mutations in the PHEX gene","volume":"41","author":"Popowska","year":"2000","journal-title":"J Appl Genet"},{"issue":"1","key":"10.1016\/j.metabol.2019.03.009_bb0215","first-page":"73","article-title":"X-linked hypophosphatemia in Polish patients. 2. Analysis of clinical features and genotype-phenotype correlation","volume":"42","author":"Popowska","year":"2001","journal-title":"J Appl Genet"},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0220","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00223-009-9260-8","article-title":"Mutational analysis of the PHEX gene: novel point mutations and detection of large deletions by MLPA in patients with X-linked hypophosphatemic rickets","volume":"85","author":"Clausmeyer","year":"2009","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0225","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/01.PDR.0000169983.40758.7B","article-title":"A clinical and molecular genetic study of hypophosphatemic rickets in children","volume":"58","author":"Cho","year":"2005","journal-title":"Pediatr Res"},{"key":"10.1016\/j.metabol.2019.03.009_bb0230","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bone.2015.05.040","article-title":"Clinical and molecular heterogeneity in a large series of patients with hypophosphatemic rickets","volume":"79","author":"Capelli","year":"2015","journal-title":"Bone."},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0235","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1530\/EJE-09-0261","article-title":"Familial hypophosphatemic rickets caused by a large deletion in PHEX gene","volume":"161","author":"Saito","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.metabol.2019.03.009_bb0240","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1002\/ajmg.a.36721","article-title":"Unusually severe hypophosphatemic rickets caused by a novel and complex re-arrangement of the PHEX gene","volume":"164A","author":"Pekkarinen","year":"2014","journal-title":"Am J Med Genet A"},{"issue":"1\u20132","key":"10.1016\/j.metabol.2019.03.009_bb0245","first-page":"211","article-title":"Hypophosphatemic rickets caused by a novel splice donor site mutation and activation of two cryptic splice donor sites in the PHEX gene","volume":"28","author":"Zou","year":"2015","journal-title":"J Pediatr Endocrinol Metab JPEM"},{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0250","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1210\/jc.2005-1776","article-title":"Somatic and germline mosaicism for a mutation of the PHEX gene can lead to genetic transmission of X-linked hypophosphatemic rickets that mimics an autosomal dominant trait","volume":"91","author":"Goji","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.metabol.2019.03.009_bb0255","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1210\/jcem.86.8.7730","article-title":"X-linked hypophosphatemia attributable to pseudoexons of the PHEX gene","volume":"86","author":"Christie","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0260","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/0030-4220(88)90237-X","article-title":"Oral findings in patients with autosomal dominant hypophosphatemic bone disease and X-linked hypophosphatemia: further evidence that they are different diseases","volume":"66","author":"Schwartz","year":"1988","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0265","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00004770-200404000-00015","article-title":"Dental alterations associated with X-linked hypophosphatemic rickets","volume":"30","author":"Pereira","year":"2004","journal-title":"J Endod"},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0270","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1148\/radiology.195.3.7754003","article-title":"Chiari I malformation: association with hypophosphatemic rickets and MR imaging appearance","volume":"195","author":"Caldemeyer","year":"1995","journal-title":"Radiology."},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0275","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/jbmr.3614","article-title":"High incidence of cranial synostosis and Chiari I malformation in children with X-linked Hypophosphatemic rickets (XLHR)","volume":"34","author":"Rothenbuhler","year":"2019","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.metabol.2019.03.009_bb0280","first-page":"2015","article-title":"Chiari malformation, syringomyelia and bulbar palsy in X linked hypophosphataemia","volume":"11","author":"Watts","year":"2015","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0285","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000334941","article-title":"Papilledema in the setting of x-linked hypophosphatemic rickets with craniosynostosis","volume":"2","author":"Glass","year":"2011","journal-title":"Case Rep Ophthalmol"},{"issue":"5","key":"10.1016\/j.metabol.2019.03.009_bb0290","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00381-015-2934-9","article-title":"X-linked hypophosphatemic rickets and sagittal craniosynostosis: three patients requiring operative cranial expansion: case series and literature review","volume":"32","author":"Jaszczuk","year":"2016","journal-title":"Childs Nerv Syst ChNS Off J Int Soc Pediatr Neurosurg"},{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0295","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/SCS.0b013e31819b9868","article-title":"X-linked hypophosphatemic rickets and craniosynostosis","volume":"20","author":"Murthy","year":"2009","journal-title":"J Craniofac Surg"},{"issue":"6","key":"10.1016\/j.metabol.2019.03.009_bb0300","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3171\/2015.10.PEDS15273","article-title":"Hypophosphatemic rickets and craniosynostosis: a multicenter case series","volume":"17","author":"Vega","year":"2016","journal-title":"J Neurosurg Pediatr"},{"issue":"1","key":"10.1016\/j.metabol.2019.03.009_bb0305","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1440-1754.1997.tb00997.x","article-title":"Craniosynostosis in X-linked hypophosphataemic rickets","volume":"33","author":"Willis","year":"1997","journal-title":"J Paediatr Child Health"},{"issue":"1","key":"10.1016\/j.metabol.2019.03.009_bb0310","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1017\/S0022215107001636","article-title":"Hearing loss and fluctuating hearing levels in X-linked hypophosphataemic osteomalacia","volume":"123","author":"Pantel","year":"2009","journal-title":"J Laryngol Otol"},{"issue":"4 Pt 1","key":"10.1016\/j.metabol.2019.03.009_bb0315","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/000348948609500418","article-title":"Audiologic findings in young patients with hypophosphatemic bone disease","volume":"95","author":"Meister","year":"1986","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"10","key":"10.1016\/j.metabol.2019.03.009_bb0320","first-page":"622","article-title":"Hearing impairment in familial X-linked hypophosphatemic rickets","volume":"163","author":"Fishman","year":"2004","journal-title":"Eur J Pediatr"},{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0325","doi-asserted-by":"crossref","first-page":"230","DOI":"10.7326\/0003-4819-100-2-230","article-title":"Impaired hearing in X-linked hypophosphataemic (vitamin-D-resistant) osteomalacia","volume":"100","author":"Davies","year":"1984","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.metabol.2019.03.009_bb0330","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1001\/archpedi.1987.04460010108039","article-title":"Renal hypophosphatemic rickets. Growth and mineral metabolism after treatment with calcitriol (1,25-dihydroxyvitamin D3) and phosphate supplementation","volume":"141","author":"Tsuru","year":"1987","journal-title":"Am J Child"},{"issue":"26","key":"10.1016\/j.metabol.2019.03.009_bb0335","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1056\/NEJM199112263252604","article-title":"Effects of therapy in X-linked hypophosphatemic rickets","volume":"325","author":"Verge","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.metabol.2019.03.009_bb0340","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11154-017-9408-1","article-title":"X-linked hypophosphatemia and growth","volume":"18","author":"Fuente","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0345","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00467-010-1705-9","article-title":"Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets","volume":"26","author":"Zivicnjak","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0350","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1542\/peds.94.4.478","article-title":"The effect of phosphate supplementation on linear growth in children with X-linked hypophosphatemia","volume":"94","author":"Seikaly","year":"1994","journal-title":"Pediatrics."},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0355","first-page":"839","article-title":"Effects of calcitriol and phosphorus therapy on the growth of patients with X-linked hypophosphatemia","volume":"76","author":"Friedman","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0360","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00431-006-0357-z","article-title":"Growth in X-linked hypophosphatemic rickets","volume":"166","author":"Ariceta","year":"2007","journal-title":"Eur J Pediatr"},{"issue":"7","key":"10.1016\/j.metabol.2019.03.009_bb0365","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2106\/00004623-198062070-00010","article-title":"Primary hypophosphatemic rickets. Effect of oral phosphate and vitamin D on growth and surgical treatment","volume":"62","author":"Evans","year":"1980","journal-title":"J Bone Joint Surg Am"},{"issue":"6","key":"10.1016\/j.metabol.2019.03.009_bb0370","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/BF01959355","article-title":"The pattern of growth and growth retardation of patients with hypophosphataemic vitamin D-resistant rickets: a longitudinal study","volume":"151","author":"Steendijk","year":"1992","journal-title":"Eur J Pediatr"},{"issue":"5","key":"10.1016\/j.metabol.2019.03.009_bb0375","doi-asserted-by":"crossref","first-page":"E990","DOI":"10.1210\/jc.2012-4146","article-title":"The muscle-bone relationship in X-linked hypophosphatemic rickets","volume":"98","author":"Veilleux","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.metabol.2019.03.009_bb0380","doi-asserted-by":"crossref","first-page":"E1492","DOI":"10.1210\/jc.2012-1336","article-title":"Abnormalities in muscle density and muscle function in hypophosphatemic rickets","volume":"97","author":"Veilleux","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0385","first-page":"439","article-title":"Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization","volume":"15","author":"Whyte","year":"1994","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.metabol.2019.03.009_bb0390","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/BF00214187","article-title":"Mutations in three subdomains of the carboxy-terminal region of collagen type X account for most of the Schmid metaphyseal dysplasias","volume":"96","author":"Bonaventure","year":"1995","journal-title":"Hum Genet"},{"issue":"6","key":"10.1016\/j.metabol.2019.03.009_bb0395","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/jbmr.5650070602","article-title":"X-linked hypophosphatemic rickets: a study (with literature review) of linear growth response to calcitriol and phosphate therapy","volume":"7","author":"Petersen","year":"1992","journal-title":"J Bone Min Res"},{"issue":"18","key":"10.1016\/j.metabol.2019.03.009_bb0400","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM198010303031802","article-title":"Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets","volume":"303","author":"Glorieux","year":"1980","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.metabol.2019.03.009_bb0405","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1172\/JCI111900","article-title":"Healing of bone disease in X-linked hypophosphatemic rickets\/osteomalacia. Induction and maintenance with phosphorus and calcitriol","volume":"75","author":"Harrell","year":"1985","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0410","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1542\/peds.71.4.559","article-title":"Long-term influence of calcitriol (1,25-dihydroxyvitamin D) and supplemental phosphate in X-linked hypophosphatemic rickets","volume":"71","author":"Chesney","year":"1983","journal-title":"Pediatrics."},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0415","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/adc.56.3.203","article-title":"Autosomal hypophosphataemic bone disease responds to 1,25-(OH)2D3","volume":"56","author":"Scriver","year":"1981","journal-title":"Arch Child"},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0420","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0022-3476(05)82822-7","article-title":"Linear growth in patients with hypophosphatemic vitamin D-resistant rickets: influence of treatment regimen and parental height","volume":"116","author":"Balsan","year":"1990","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0425","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1210\/jcem-52-3-463","article-title":"X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization","volume":"52","author":"Costa","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0430","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-2265.2003.01685.x","article-title":"Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets","volume":"58","author":"Makitie","year":"2003","journal-title":"Clin Endocrinol Oxf"},{"issue":"5","key":"10.1016\/j.metabol.2019.03.009_bb0435","first-page":"252","article-title":"Growth and metabolic control during puberty in girls with X-linked hypophosphataemic rickets","volume":"61","author":"Sochett","year":"2004","journal-title":"Horm Res"},{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0440","doi-asserted-by":"crossref","first-page":"146","DOI":"10.5395\/rde.2017.42.2.146","article-title":"Dental management of patients with X-linked hypophosphatemia","volume":"42","author":"Lee","year":"2017","journal-title":"Restor Dent Endod"},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0445","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.tripleo.2008.12.003","article-title":"Familial hypophosphatemic vitamin D-resistant rickets\u2014prevention of spontaneous dental abscesses on primary teeth: a case report","volume":"107","author":"Douyere","year":"2009","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"10","key":"10.1016\/j.metabol.2019.03.009_bb0450","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1210\/JC.2015-2199","article-title":"Conventional therapy in adults with X-linked hypophosphatemia: effects on enthesopathy and dental disease","volume":"100","author":"Connor","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0455","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/000992289203100311","article-title":"Nephrocalcinosis, hyperparathyroidism, and renal failure in familial hypophosphatemic rickets","volume":"31","author":"Alon","year":"1992","journal-title":"Clin Pediatr (Phila)"},{"issue":"7","key":"10.1016\/j.metabol.2019.03.009_bb0460","first-page":"A4874","article-title":"Treatment of hypophosphataemic rickets in children remains a challenge","volume":"61","author":"Nielsen","year":"2014","journal-title":"Dan Med J"},{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0465","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00860736","article-title":"Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus disease","volume":"9","author":"Taylor","year":"1995","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.metabol.2019.03.009_bb0470","first-page":"91","article-title":"Associated with renal tubular acidosis in children with X-linked hypophosphatemia","volume":"97","author":"Seikaly","year":"1996","journal-title":"Pediatrics."},{"issue":"5","key":"10.1016\/j.metabol.2019.03.009_bb0475","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0022-3476(87)80245-7","article-title":"Nephrocalcinosis and its relationship to treatment of hereditary rickets","volume":"111","author":"Goodyer","year":"1987","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0480","doi-asserted-by":"crossref","first-page":"274","DOI":"10.14310\/horm.2002.1277","article-title":"Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review","volume":"9","author":"Yavropoulou","year":"2010","journal-title":"Horm Athens Greece"},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0485","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4158\/EP.12.3.294","article-title":"Tertiary hyperparathyroidism attributable to long-term oral phosphate therapy","volume":"12","author":"McHenry","year":"2006","journal-title":"Endocr Pract"},{"issue":"6","key":"10.1016\/j.metabol.2019.03.009_bb0490","first-page":"1514","article-title":"Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets","volume":"75","author":"Rivkees","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.metabol.2019.03.009_bb0495","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1210\/jc.2014-2017","article-title":"Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study","volume":"99","author":"Carpenter TO","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0500","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2215\/CJN.04981107","article-title":"Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets","volume":"3","author":"Alon","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0505","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1302\/1863-2548.11.170003","article-title":"The orthopaedic management of lower limb deformity in hypophosphataemic rickets","volume":"11","author":"Horn","year":"2017","journal-title":"J Child Orthop"},{"key":"10.1016\/j.metabol.2019.03.009_bb0510","unstructured":"New medicine for rare bone disease|European Medicines Agency [Internet]. [cited 2018 Oct 4]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/new-medicine-rare-bone-disease"},{"key":"10.1016\/j.metabol.2019.03.009_bb0515","author":"Commissioner O of the. Press Announcements"},{"issue":"21","key":"10.1016\/j.metabol.2019.03.009_bb0520","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0525","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.metabol.2019.03.009_bb0530","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2019.03.009_bb0535","doi-asserted-by":"crossref","first-page":"h3394","DOI":"10.1136\/bmj.h3394","article-title":"Normal lower limb variants in children","volume":"350","author":"Yeo","year":"2015","journal-title":"BMJ."},{"issue":"6","key":"10.1016\/j.metabol.2019.03.009_bb0540","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00431-014-2454-8","article-title":"Sex-, age-, and height-specific reference curves for the 6-min walk test in healthy children and adolescents","volume":"174","author":"Saraff","year":"2015","journal-title":"Eur J Pediatr"},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0545","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1210\/jc.2009-1671","article-title":"Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations","volume":"95","author":"Imel","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.metabol.2019.03.009_bb0550","doi-asserted-by":"crossref","first-page":"E352","DOI":"10.1210\/jc.2010-0589","article-title":"Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status","volume":"95","author":"Carpenter","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.metabol.2019.03.009_bb0555","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00467-004-1443-y","article-title":"The enigma of hyperparathyroidism in hypophosphatemic rickets","volume":"19","author":"Schmitt","year":"2004","journal-title":"Pediatr Nephrol Berl Ger."},{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0560","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0022-3476(97)70162-8","article-title":"Urinary phosphate\/creatinine, calcium\/creatinine, and magnesium\/creatinine ratios in a healthy pediatric population","volume":"131","author":"Matos","year":"1997","journal-title":"J Pediatr"},{"key":"10.1016\/j.metabol.2019.03.009_bb0565","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bonr.2016.05.004","article-title":"Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia","volume":"5","author":"Ruppe","year":"2016","journal-title":"Bone Rep"},{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0570","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jcph.570","article-title":"Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia","volume":"56","author":"Zhang","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.metabol.2019.03.009_bb0575","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00247-007-0503-4","article-title":"Sagittal synostosis in X-linked hypophosphatemic rickets and related diseases","volume":"37","author":"Currarino","year":"2007","journal-title":"Pediatr Radiol"},{"issue":"6","key":"10.1016\/j.metabol.2019.03.009_bb0580","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1542\/peds.113.6.e593","article-title":"Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets","volume":"113","author":"Haffner","year":"2004","journal-title":"Pediatrics."},{"issue":"12","key":"10.1016\/j.metabol.2019.03.009_bb0585","doi-asserted-by":"crossref","first-page":"E2097","DOI":"10.1210\/jc.2011-0399","article-title":"Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion","volume":"96","author":"\u017divi\u010dnjak","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2019.03.009_bb0590","first-page":"212","article-title":"Metabolic control and growth during exclusive growth hormone treatment in X-linked hypophosphatemic rickets","volume":"69","author":"Makitie","year":"2008","journal-title":"Horm Res"},{"key":"10.1016\/j.metabol.2019.03.009_bb0595","article-title":"Recombinant growth hormone therapy for X-linked hypophosphatemia in children","volume":"1","author":"Huiming","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.metabol.2019.03.009_bb0600","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s004670050340","article-title":"X-linked hypophosphatemia: effects of treatment with recombinant human growth hormone","volume":"11","author":"Reusz","year":"1997","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0605","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0022-3476(95)70070-6","article-title":"Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density","volume":"127","author":"Saggese","year":"1995","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.metabol.2019.03.009_bb0610","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1542\/peds.100.5.879","article-title":"The effect of recombinant human growth hormone in children with X-linked hypophosphatemia","volume":"100","author":"Seikaly","year":"1997","journal-title":"Pediatrics."},{"key":"10.1016\/j.metabol.2019.03.009_bb0615","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ghir.2017.08.001","article-title":"Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR)","volume":"36","author":"Rothenbuhler","year":"2017","journal-title":"Growth Horm IGF Res Off J Growth Horm Res Soc Int IGF Res Soc"},{"issue":"3","key":"10.1016\/j.metabol.2019.03.009_bb0620","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00467-017-3820-3","article-title":"Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets","volume":"33","author":"Meyerhoff","year":"2018","journal-title":"Pediatr Nephrol Berl Ger."},{"issue":"11\u221212","key":"10.1016\/j.metabol.2019.03.009_bb0625","first-page":"1333","article-title":"Risk factors affecting the development of nephrocalcinosis, the most common complication of hypophosphatemic rickets","volume":"28","author":"Keskin","year":"2015","journal-title":"J Pediatr Endocrinol Metab JPEM"},{"issue":"2","key":"10.1016\/j.metabol.2019.03.009_bb0630","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41581-018-0087-2","article-title":"Renal and extrarenal effects of fibroblast growth factor 23","volume":"15","author":"Vervloet","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.metabol.2019.03.009_bb0635","series-title":"Gil-Pe\u00f1a H","author":"Hern\u00e1ndez-Fr\u00edas","year":"2019"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049519300654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049519300654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:22:24Z","timestamp":1758428544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049519300654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":127,"alternative-id":["S0026049519300654"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2019.03.009","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH)","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2019.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"153892"}}